ATLANTA, Sept. 19, 2012 /PRNewswire/ -- Elekta recently announced the latest production release of its Monaco® treatment planning system, version 3.20, which offers customers improved VMAT planning and delivery support in addition to support for Elekta's Agility* 160-leaf multi-leaf collimator. This release promises to create new workflow efficiencies through integrated plan approval and enhanced integration with MOSAIQ® Oncology Information System.
The new Segment Shape Optimization is driving improved dose conformity, plan quality and delivery efficiency through its proprietary approach to smoothing and clustering segments then optimizing beam weights and shapes. Powered by the Monte Carlo algorithm, the results are plans that improve sparing of organs-at-risk and dose conformality.
In addition, the release's new contouring tool, EZ Sketch, and Room's Eye View increase workflow efficiency. Support for Agility means that Monaco 3.20 users can achieve a new level of beam-shaping precision and delivery speed.
Staff at Kettering Medical Center (Dayton, Ohio) used a pilot version of Monaco 3.20.
"We have been using Monaco 3.20 clinically since June 2012," says Christopher Wennerstrom, MS, DABR, Medical Physicist at Kettering Medical Center. "It has consistently provided excellent tumor coverage while meeting our physicians' very strict OAR tolerances. The new Target Penalty cost function and segment shape optimizer allow us to treat more patients with VMAT than ever before, and even our most complex SBRT cases have extremely quick treatment times."
Monaco is a state-of-the-art IMRT, VMAT and SBRT planning solution that features innovative biological cost functions with multi-criterial constrained optimization, a powerful leaf sequence optimizer and a robust Monte Carlo dose calculation algorithm. Monaco helps make the planning process easier, more straightforward and clinically reliable.
For more information on Elekta's latest treatment planning releases, visit: www.elekta.com/rtp.
*Agility is not licensed for sale in all markets. Please contact your local representative for details.
For further information, please contact:
Johan Andersson Melbi, Investor Relations Manager, Elekta AB
Tel: +46 702 100 451, email: firstname.lastname@example.org
Time zone: CET: Central European Time
Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: email@example.com
Time zone: ET: Eastern Time
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,300 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.